Lonza’s dedication to mRNA innovation is transforming the future of vaccine development, cancer treatments, and other emerging therapies, establishing the company as a significant force in the biopharmaceutical sector.
In this white paper, experts from Lonza explore the challenges and opportunities related to nucleic acid encapsulation technologies, with a specific emphasis on mRNA encapsulation. They provide insights into the essential requirements of Lonza’s LNP toolbox and explain how this strategy supports a low-risk transition from pre-clinical phases to cGMP production.
Author(s):
Alexander Schwenger, Ph.D.
Head of Process Development – LNP
Telmo Graça, Ph.D.
Process and Technology Lead – mRNA
To connect with Lonza’s experts, please contact your dedicated Business Development Specialist, Amanda, at amanda.holmstein@lonza.com .